Abstract
Lewis lung carcinoma (LLC-LN7) tumors stimulate myelopoiesis and induce immunosuppressive granulocyte-macrophage (GM)-progenitor cells. Treating mice having palpable tumors with IL-12 enhanced the frequency of GM-progenitors and did not diminish GM-suppressor activity. Proliferation of splenic T-cells of tumor-bearers to Con-A or to anti-CD3 plus IL-2 was suppressed; this was not enhanced by IL-12 treatment. Also not stimulated was T-cell secretion of IL-2 in response to autologous tumor, or the intratumoral T-cell content. IL-12 slightly increased splenic IFN-gamma secretion, and increased cytotoxicity of lymph node (but not spleen) cells toward autologous tumor. In these tumor-bearing mice that were immune depressed as a result of GM-suppressor cells, immune modulatory effects of IL-12 were marginal and did not affect tumor size or metastasis.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
Carcinoma, Lewis Lung / drug therapy*
-
Carcinoma, Lewis Lung / immunology*
-
Carcinoma, Lewis Lung / pathology
-
Cell Division / drug effects
-
Granulocytes / cytology
-
Granulocytes / immunology*
-
Hematopoietic Stem Cells / cytology
-
Hematopoietic Stem Cells / immunology*
-
Immune Tolerance / drug effects
-
Immunity, Cellular / drug effects
-
Interleukin-12 / pharmacology*
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / immunology*
-
Lung Neoplasms / pathology
-
Macrophages / cytology
-
Macrophages / immunology*
-
Mice
-
Mice, Inbred C57BL
-
T-Lymphocytes / cytology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
-
T-Lymphocytes, Regulatory / cytology
-
T-Lymphocytes, Regulatory / drug effects
-
T-Lymphocytes, Regulatory / immunology
Substances
-
Adjuvants, Immunologic
-
Interleukin-12